|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.41 USD | +0.71% |
|
+6.02% | +5.22% |
| Apr. 24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
| Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Precigen, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 6.23 million compared to USD 26.91 million a year ago. Net loss was USD 95.9 million compared to net income of USD 28.32 million a year ago.
Basic loss per share from continuing operations was USD 0.39 compared to USD 0.4 a year ago. Basic loss per share was USD 0.39 compared to basic earnings per share of USD 0.14 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +5.22% | 351M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
PRECIGEN, INC. 
